Emerging molecular markers of cancer

From Bioconference_org

Jump to: navigation, search

http://www.nextgenerationdx.com/cdx

PRELIMINARY AGENDA JUST RELEASED - VIEW AGENDA

4th annual Emerging Molecular Markers of Cancer
Part of CHI's 3rd annual Next Generation Dx Summit | August 23-25, 2011 | Washington, DC

View Preliminary Agenda   |   Register Early and Save!   |   NextGenerationDx.com

The realm of cancer diagnostic testing is vastly different today because of new tools available that can profile and
characterize cancer on a molecular basis. Markers will be compared and evaluated using deep sequencing of cancer,
cancer stem cells and circulating tumor cells. These can be used to guide therapy, predict response and provide
accurate diagnosis. Emerging molecular markers of cancer will be assessed for their potential use for clinical settings.
This field is revolutionizing cancer treatment and will lead the way to applying these techniques in other disease areas.

Scientific Advisor
Hakan Sakul, Ph.D., Senior Director, Translational Oncology Group, Pfizer - Oncology Business Unit

PRELIMINARY AGENDA

DEEP SEQUENCING

PLENARY KEYNOTE SESSION

KEYNOTE PANEL:
Changing Regulation of LDTs
Moderator:
Franklin R. Cockerill, III, M.D., Ann and Leo Markin Professor of Microbiology & Medicine;
Chair, Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine;
President and CEO, Mayo Medical Laboratories and Mayo Collaborative Services, Inc.

Featured Panelist: Alberto Gutierrez, Ph.D., Deputy Director, New Product Evaluation,
Office of In Vitro Diagnostic Device Evaluation and Safety, Food & Drug Administration

MULTI-STAKEHOLDER REIMBURSEMENT PANEL:
Future of Reimbursement for Molecular Diagnostics

Moderator: Thomas A. Gustafson, Ph.D., Senior Policy Advisor, Arnold & Porter LLP

  • Status of CPT coding and fee schedules (clinical lab vs. physician fee)
  • Impact of new CPT coding for reimbursement of tests
  • What do changes in regulation portend for suppliers and reimbursement?

Panelists: Ann-Marie Lynch, Executive Vice President, Payment & Healthcare Delivery Policy, AdvaMed
David Mongillo, M.P.H., M.S.M., Vice President, Policy and Medical Affairs, American Clinical
Laboratory Association
Marc Hartstein, Acting Director, Hospital and Ambulatory Policy Group, Center for Medicare, Centers for
Medicare and Medicaid Services (tentative)



PRE-CONFERENCE SHORT COURSES 
|
Monday, August 22 
9:00am-12:00pm
: Micro- and Nanofluidics in Diagnostics and Life Sciences: Technologies, Applications and Markets 
2:00-5:00pm: Applications of Detection Theory in Diagnostics 

DINNER SHORT COURSES | Wednesday, August 24
6:30-8:30pm
: The Future of Point-of-Care Platforms
6:30-8:30pm: Mass Spec Methods for the Clinical Lab


Click here for detailed information on the Short Courses.



SPONSORSHIP AND EXHIBIT INFORMATION
For information on sponsorships and exhibits, contact:
Joseph Vacca
, Manager, Business Development | Phone: 781-972-5431 | E-mail:
jvacca@healthtech.com

 

 

Be a part of the third annual Next Generation Dx Summit

Next Generation Dx Summit 2011: Moving Assays to the Clinic
 


Click here to download the preliminary agenda  |  Register by April 29 and Save up to $450!  

NextGenerationDx.com

Chairperson: Lyle Arnold, Ph.D., President & Founder, Aegea Biotechnologies; Member, Board of Directors, Asuragen, Inc.

Clinician's Dilemma: Challenges and Practical Aspects of Sequencing
Ramesh K. Ramanathan, M.D., Medical Director, TGen Clinical Research Service, Scottsdale Health Care and Clinical
Professor of Medicine, University of Arizona, College of Medicine

Development of Personalized Tumor Biomarkers Using Massively Parallel Sequencing
Rebecca Leary, Ph.D., Postdoctoral Fellow, Oncology, Ludwig Center for Cancer Genetics and Therapeutics,
Johns Hopkins Kimmel Cancer Center

Cancer Informatics
Peter Blume-Jensen, Ph.D., CSO, Metamark Genetics

Using NGS for Biomarker Discovery in Solid Tumors
Joff Baker, Ph.D., CSO, Genomic Health, Inc.

CANCER BIOMARKERS

Comparing IHC and FISH for the Diagnosis of ALK+ Lung Adenocarcinoma and Correlations with Responses
to Targeted Therapy
Scott J. Rodig, M.D., Ph.D., Assistant Professor, Pathology, Harvard Medical School; Attending Physician,
Brigham and Women's Hospital

Patient Selection Biomarkers for Drugs Targeting PI3K and KRAS Signaling
Gary V. Borzillo, Ph.D., Associate Director, Translational Oncology, Pfizer, Inc.

Cancer Diagnosis Based on Analysis of the Plasma Soluble HLA Peptidome
Arie Admon, Technion-Israel Institute of Technology

CIRCULATING BIOMARKERS

The Role of Platelets in Circulating Tumor Cell Diagnostics
Joseph M. Carroll, Ph.D., Associate Director, Biomedical Diagnostics Institute, Dublin City University (DCU)

Biomarkers of Cancer Malignancy for Clinical, Molecular Diagnosis
Marek Malecki, M.D., Ph.D., Associate Professor of Genetics, Genomics, and Gene Therapy;
Director of Biotechnology Program, Western University of Health Sciences

Targeting Circulating Tumor Cells in Blood Using Selectin Adhesion and Natural Halloysite Nanotubes
Michael King, Ph.D., Associate Professor, Biomedical Engineering, Cornell University

The Clinical Significance of CTCs in the Metastatic NSCLC
Siminder Kaur Atwal, Ph.D., Senior Research Associate, Oncology Biormarker Development, Genentech, Inc.

Sponsored Presentation     Sponsored by Exosome Diagnostics, Inc.
Speaker to be Announced

Sponsored Presentation     Sponsored by Veridex, LLC
Speaker to be Announced

 

 

 
Cambridge Healthtech Institute, 250 First Avenue, Suite 300, Needham, MA 02494

This email communication is for commercial purposes. If it is not of interest to you, please disregard and we apologize

for any inconvenience this may have caused. To prevent further emails, please click here
Personal tools
Google AdSense